Harshana S De Silva Feelixge
Overview
Explore the profile of Harshana S De Silva Feelixge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stone D, Long K, Loprieno M, De Silva Feelixge H, Kenkel E, Liley R, et al.
Mol Ther Methods Clin Dev
. 2021 Jan;
20:258-275.
PMID: 33473359
Chronic hepatitis B virus (HBV) infection is a major public health problem. New treatment approaches are needed because current treatments do not target covalently closed circular DNA (cccDNA), the template...
2.
Stone D, Kenkel E, Loprieno M, Tanaka M, De Silva Feelixge H, Kumar A, et al.
Hum Gene Ther
. 2020 Oct;
32(1-2):96-112.
PMID: 32998579
Adeno-associated virus (AAV) vectors such as AAV6, which shows tropism for primary human CD4 T cells , are being explored for delivery of anti-HIV therapeutic modalities . However, pre-existing immunity...
3.
Aubert M, Strongin D, Roychoudhury P, Loprieno M, Haick A, Klouser L, et al.
Nat Commun
. 2020 Aug;
11(1):4148.
PMID: 32811834
We evaluate gene editing of HSV in a well-established mouse model, using adeno-associated virus (AAV)-delivered meganucleases, as a potentially curative approach to treat latent HSV infection. Here we show that...
4.
De Silva Feelixge H, Stone D, Roychoudhury P, Aubert M, Jerome K
ACS Infect Dis
. 2018 Mar;
4(6):871-880.
PMID: 29522311
Chronic viral infections remain a major public health issue affecting millions of people worldwide. Highly active antiviral treatments have significantly improved prognosis and infection-related morbidity and mortality but have failed...
5.
De Silva Feelixge H, Jerome K
Mol Ther
. 2017 May;
25(5):1062-1064.
PMID: 28462817
No abstract available.
6.
Dang C, Aubert M, De Silva Feelixge H, Diem K, Loprieno M, Roychoudhury P, et al.
Sci Rep
. 2017 Apr;
7(1):927.
PMID: 28424485
The ability to genetically manipulate trigeminal ganglion (TG) neurons would be useful in the study of the craniofacial nervous system and latent alphaherpesvirus infections. We investigated adeno-associated virus (AAV) vectors...
7.
Roychoudhury P, De Silva Feelixge H, Pietz H, Stone D, Jerome K, Schiffer J
J Antimicrob Chemother
. 2016 Apr;
71(8):2089-99.
PMID: 27090632
Objectives: A promising curative approach for HIV is to use designer endonucleases that bind and cleave specific target sequences within latent genomes, resulting in mutations that render the virus replication...
8.
Sedlak R, Liang S, Niyonzima N, De Silva Feelixge H, Roychoudhury P, Greninger A, et al.
Sci Rep
. 2016 Feb;
6:20064.
PMID: 26829887
Genome editing by designer nucleases is a rapidly evolving technology utilized in a highly diverse set of research fields. Among all fields, the T7 endonuclease mismatch cleavage assay, or Surveyor...
9.
Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy
De Silva Feelixge H, Stone D, Pietz H, Roychoudhury P, Greninger A, Schiffer J, et al.
Antiviral Res
. 2016 Jan;
126:90-8.
PMID: 26718067
Incurable chronic viral infections are a major cause of morbidity and mortality worldwide. One potential approach to cure persistent viral infections is via the use of targeted endonucleases. Nevertheless, a...
10.
Weber N, Stone D, Sedlak R, De Silva Feelixge H, Roychoudhury P, Schiffer J, et al.
PLoS One
. 2014 May;
9(5):e97579.
PMID: 24827459
Despite an existing effective vaccine, hepatitis B virus (HBV) remains a major public health concern. There are effective suppressive therapies for HBV, but they remain expensive and inaccessible to many,...